StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3010% above fair value
$957.76+5.36 (+0.56%)

Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –

Regeneron Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Regeneron Pharmaceuticals's pe ratio was 23.7× on Nov 11, 2026, against 18.7× a year earlier. Over the last 5 years it ranged from 8.2× to 31.9×, with a median of 18.6×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202623.7×+5.2
2025Dec 31, 202518.5×+0.9
2024Dec 31, 202417.6×−7.4
2023Dec 29, 202325.1×+9.8
2022Dec 30, 202215.2×+5.1
2021Dec 31, 202110.1×−7.6
2020Dec 31, 202017.7×−2.4
2019Dec 31, 201920.1×−3.8
2018Dec 31, 201823.9×−10.3
2017Dec 29, 201734.1×−19.1
2016Dec 30, 201653.3×−56.4
2015Dec 31, 2015109.7×−24.8
2014Dec 31, 2014134.5×+95.3
2013Dec 31, 201339.2×−48.5
2012Dec 31, 201287.7×–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?